Heterocyclic compounds can be divided into two categories: alicyclic heterocycles and aromatic heterocycles. Compounds whose heterocycles in the molecular skeleton cannot reflect aromaticity are called alicyclic heterocyclic compounds. Compound: 41575-94-4, is researched, Molecular C6H12N2O4Pt, about Prospective feasibility study of neoadjuvant dose-dense paclitaxel plus carboplatin with bevacizumab therapy followed by interval debulking surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer patients, the main research direction is ovarian fallopian tube primary peritoneal cancer paclitaxel carboplatin; bevacizumab neoadjuvant chemotherapy dose interval debulking surgery; Bevacizumab; Dose-dense TC; Feasibility; Neoadjuvant chemotherapy; Ovarian cancer.Related Products of 41575-94-4.
Abstract: Background: This study aimed to investigate the clin. benefit of dose-dense paclitaxel plus carboplatin (TC) with bevacizumab therapy for advanced ovarian, fallopian tube, and primary peritoneal cancer patients in the neoadjuvant setting. Methods: Ovarian, fallopian tube or primary peritoneal cancer patients with stage III-IV disease received neoadjuvant chemotherapy (NAC) every 3 wk consisting of paclitaxel (80 mg/m2) on days 1, 8, and 15; carboplatin (AUC 6.0 mg/mL x min.) on day 1; and bevacizumab (15 mg/kg) on day 1. Interval debulking surgery (IDS) was performed after 3 cycles of dose-dense TC-bevacizumab therapy. The primary endpoint was the rate of complete resection by IDS. Secondary endpoints were treatment completion rate, treatment exposure, response rate to NAC, adverse events, and perioperative complications. Results: Twenty-four patients were included in this study. The median age was 55.5 years (37-80 years), and most patients had high-grade serous carcinoma accounted (n = 18). IDS was performed in all patients with complete resection achieved in 75‰ (95‰ confidence interval: 57.7-92.3‰). The lower limit exceeded the preset threshold rate of 55‰. The response rate to NAC was 79‰, and serum CA125 levels were in the normal range after NAC in 57‰ of patients. Grade 4 hematol. toxicities and grade 3/4 non-hematol. toxicities occurred in 29‰ and 17‰ of patients during NAC, resp. Grade 3/4 perioperative complications were seen in 29‰ of patients, but no gastrointestinal perforations or treatment-related deaths occurred. Conclusions: Neoadjuvant dose-dense TC-bevacizumab therapy was well tolerated, and a satisfactory rate of complete resection by IDS was achieved.
In some applications, this compound(41575-94-4)Related Products of 41575-94-4 is unique.If you want to know more details about this compound, you can contact with the author or consult more relevant literature.
Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics